King warned on Embeda VNRs

Share this article:

VNRs for King's ostensibly abuse-resistant pain drug Embeda drew an FDA warning letter.

The agency said two VNRs omitted or minimized risks, including those featured in the drug's “extensive” boxed warning, and failed to present limitations to the approved indication. Moreover, the letter said King presented misleading claims – among them, about the drug's alleged but clinically unsubstantiated abuse-resistant properties.  DDMAC said King agreed to pull the VNRs in August.

DDMAC demanded the company furnish a list of materials it has pulled, and that it disseminate corrective messaging.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Pharmaceutical


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.